Q2 Sales revenues falls short. Raising new capital

Quote

anonymous

Guest
As expected sop no real surprise, Q2 revenue has fallen short of expectations (which is also being reflected in the drop in the stock price this week). If any good news can come out of this, heard that company will be raising needed cash by making an additional stock offering of common shares. So Pernix will have enough cash after new stock offering to last until the turnaround is hopefully completed or company sold by end of 2016 or 2017.
 






stop with the splashy headlines. Everyone within company knew sales revenue would still be down in Q2 and also again most likely in Q3. So no new news here. Also no surprise either that operational cash would be needed and raise thru a new stock offering. Sucks for the investors as it dilutes shares and stock prices. But good for the overall health and survival of the company.

Again, no real new news that you posted.
 






Stock market has been soaring the past three days, including the IBB index on pharma /bio companies. Yet Pernix has been down over 3% each day. But I think you nailed the reason why for us investors in your post above. Declining sales revenue and a poor Q2 and forecast of a poor Q3 is the reason for the stock sell off in price despite markets rallying big time.
 






anonymous said:
stop with the splashy headlines. Everyone within company knew sales revenue would still be down in Q2 and also again most likely in Q3. So no new news here. Also no surprise either that operational cash would be needed and raise thru a new stock offering. Sucks for the investors as it dilutes shares and stock prices. But good for the overall health and survival of the company.

Again, no real new news that you posted.
Click to expand...
 






Top Bottom
Back
Quote